Paper38548752
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Hayes TK and 26 others. Nat Commun, 2024. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. Papers, record 38548752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38548752
- Disease
- glioblastoma453 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glioblastoma | Major topic |
| Lung Neoplasms | Major topic |
| Humans | |
| Protein Kinase Inhibitors | |
| ErbB Receptors | |
| Mutation |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K99 CA248836 | NCI NIH HHS | United States | K99CA248836 | PubMed and NIH | NIH RePORTER |
| R00 CA248836 | NCI NIH HHS | United States | K99CA248836 | PubMed and NIH | NIH RePORTER |
| R35 CA197568 | NCI NIH HHS | United States | R35CA197568 | PubMed and NIH | NIH RePORTER |
| T32 CA009172 | NCI NIH HHS | United States | T32CA009172 | PubMed | NIH RePORTER |
| R00CA248836 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01112527 | PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma | Derived from the trial |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 38627431 | Author Correction: Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. | https://conductscience.org/library/papers/38627431 |
Source PubMed
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24120142 | The somatic genomic landscape of glioblastoma. | Cell | 2013 | https://conductscience.org/library/papers/24120142 | PubMed |
| 2 | 17177598 | Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. | PLoS Med | 2006 | https://conductscience.org/library/papers/17177598 | PubMed |
| 3 | 15118073 | Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15118073 | PubMed |
| 4 | 26286086 | EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. | Cancer Discov | 2015 | https://conductscience.org/library/papers/26286086 | PubMed |
| 5 | 27102076 | EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. | Cancer Discov | 2016 | https://conductscience.org/library/papers/27102076 | PubMed |
| 6 | 18403609 | EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. | J Mol Diagn | 2008 | https://conductscience.org/library/papers/18403609 | PubMed |
| 7 | 16730237 | The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. | Cancer Cell | 2006 | https://conductscience.org/library/papers/16730237 | PubMed |
| 8 | 22588883 | Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. | Cancer Discov | 2012 | https://conductscience.org/library/papers/22588883 | PubMed |
| 9 | 28481359 | Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. | Nat Med | 2017 | https://conductscience.org/library/papers/28481359 | PubMed |
| 10 | 28979142 | The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive. | Onco Targets Ther | 2017 | https://conductscience.org/library/papers/28979142 | PubMed |
| 11 | 32014348 | Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations. | Clin Lung Cancer | 2020 | https://conductscience.org/library/papers/32014348 | PubMed |
| 12 | 31092401 | Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. | Cancer Discov | 2019 | https://conductscience.org/library/papers/31092401 | PubMed |
| 13 | 19692680 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19692680 | PubMed |
| 14 | 31751012 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. | N Engl J Med | 2020 | https://conductscience.org/library/papers/31751012 | PubMed |
| 15 | 22285168 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. | Lancet Oncol | 2012 | https://conductscience.org/library/papers/22285168 | PubMed |
| 16 | 26051236 | Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26051236 | PubMed |
| 17 | 32923886 | Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. | JCO Precis Oncol | 2020 | https://conductscience.org/library/papers/32923886 | PubMed |
| 18 | 34526717 | Structure-based classification predicts drug response in EGFR-mutant NSCLC. | Nature | 2021 | https://conductscience.org/library/papers/34526717 | PubMed |
| 19 | 29141884 | A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. | Sci Transl Med | 2017 | https://conductscience.org/library/papers/29141884 | PubMed |
| 20 | 30952700 | An unbiased in vitro screen for activating epidermal growth factor receptor mutations. | J Biol Chem | 2019 | https://conductscience.org/library/papers/30952700 | PubMed |
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42940191 | Personalized Therapeutic Strategies in Glioblastoma: Bridging Molecular Markers and In Vivo Observations for Targeted Treatment. | Biomedicines | 2026 | https://conductscience.org/library/papers/42940191 | PubMed |
| 42630841 | Should we optimise or revise the management of initially unresectable stage III non-small cell lung cancer: rethinking consolidation therapy. | J Natl Cancer Cent | 2026 | https://conductscience.org/library/papers/42630841 | PubMed |
| 42453407 | Unveiling the bioactive landscape of drug inactive ingredients (DIGs) using deep transfer learning. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42453407 | PubMed |
| 42249090 | Integrative structural and dynamics studies of epidermal growth factor receptor (EGFR). | Exp Mol Med | 2026 | https://conductscience.org/library/papers/42249090 | PubMed |
| 41951591 | SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity. | Nat Commun | 2026 | https://conductscience.org/library/papers/41951591 | PubMed |
| 41760505 | Leveraging conformational ensembles in allosteric drug discovery. | Trends Pharmacol Sci | 2026 | https://conductscience.org/library/papers/41760505 | PubMed |
| 41644930 | Advancements in somatic mutation detection through loop-mediated isothermal amplification (LAMP) in human tumors. | J Appl Genet | 2026 | https://conductscience.org/library/papers/41644930 | PubMed |
| 41567248 | Database of recurrent mutations, an unbiased web resource to browse recurrent mutations in cancers. | iScience | 2026 | https://conductscience.org/library/papers/41567248 | PubMed |
| 41565660 | An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression. | Nat Commun | 2026 | https://conductscience.org/library/papers/41565660 | PubMed |
| 41278632 | Uncovering the molecular basis of kinase activity and substrate recognition with phospho-PCA. | bioRxiv | 2025 | https://conductscience.org/library/papers/41278632 | PubMed |
| 40872202 | Bioactive Potential of Nepenthes miranda Flower Extracts: Antidiabetic, Anti-Skin Aging, Cytotoxic, and Dihydroorotase-Inhibitory Activities. | Plants (Basel) | 2025 | https://conductscience.org/library/papers/40872202 | PubMed |
| 40866630 | ECM-based molecular subtypes define prognostic, EMT status, and therapeutic diversity in IDH-mutant gliomas. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/40866630 | PubMed |
| 40744495 | A side-by-side comparison of variant function measurements using deep mutational scanning and base editing. | Nucleic Acids Res | 2025 | https://conductscience.org/library/papers/40744495 | PubMed |
| 40724977 | CNS Tumor with BCOR/BCORL1 Fusion: A Rare Tumor Entity. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40724977 | PubMed |
| 40617976 | Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing. | Int J Clin Oncol | 2025 | https://conductscience.org/library/papers/40617976 | PubMed |
| 40430991 | Inhibition of RPA32 and Cytotoxic Effects of the Carnivorous Plant Sarracenia purpurea Root Extract in Non-Small-Cell Lung Cancer Cells. | Plants (Basel) | 2025 | https://conductscience.org/library/papers/40430991 | PubMed |
| 40182139 | Pancreatic Cancer: Pathogenesis and Clinical Studies. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40182139 | PubMed |
| 40053698 | Prospective Evaluation of Structure-Based Simulations Reveal Their Ability to Predict the Impact of Kinase Mutations on Inhibitor Binding. | J Phys Chem B | 2025 | https://conductscience.org/library/papers/40053698 | PubMed |
| 39727987 | Towards Effective Treatment of Glioblastoma: The Role of Combination Therapies and the Potential of Phytotherapy and Micotherapy. | Curr Issues Mol Biol | 2024 | https://conductscience.org/library/papers/39727987 | PubMed |
| 39695128 | USP21-EGFR signaling axis is functionally implicated in metastatic colorectal cancer. | Cell Death Discov | 2024 | https://conductscience.org/library/papers/39695128 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| DACOMITINIB ANHYDROUS | CHEMBL2110732 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2110732 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38548752
GET https://conductscience.org/api/papers/v1/38548752/authors?page=2